text_1: Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
text_2: This story briefly reports on an announcement from a drug company that an ongoing study shows longer progression-free survival of patients with advanced renal cell carcinoma if those patients are receiving a combination of two drugs: avelumab (sold under the trade name Bavencio) and axitinib (sold under the trade name Inlyta). The story is focused on investors and meant to deliver a quick update on market-moving news. Yet the story will also show up in the searches of many patients who suffer from kidney cancer and can be misled by such one-sided coverage. Primarily because the story takes the company’s word for the announced benefit without evaluating the claims and fails to address cost or side effects in any way, despite the fact that both drugs are already on the market. This story fails to provide important contextual information related to the relevant product’s cost, safety and availability. This story is, essentially, a news release. That does a disservice to the story’s readers and to the newsroom it came from.